Shares of MediWound Ltd. (NASDAQ:MDWD) traded down 17.4% during trading on Tuesday . The stock traded as low as $4.95 and last traded at $5.00. 1,128,715 shares were traded during trading, an increase of 3,211% from the average session volume of 34,095 shares. The stock had previously closed at $6.05.

Several analysts have commented on the stock. SunTrust Banks, Inc. reissued a “buy” rating on shares of MediWound in a research report on Monday, June 26th. Aegis reissued a “buy” rating and set a $11.00 price target on shares of MediWound in a research report on Thursday, May 25th. Zacks Investment Research raised shares of MediWound from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $10.00 price target on shares of MediWound and gave the company a “buy” rating in a research report on Friday, August 25th. Finally, Oppenheimer Holdings, Inc. reissued a “buy” rating and set a $10.00 price target on shares of MediWound in a research report on Monday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $9.19.

The company’s 50 day moving average is $6.30 and its 200-day moving average is $6.53. The stock’s market capitalization is $109.77 million.

MediWound (NASDAQ:MDWD) last announced its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The company had revenue of $0.69 million during the quarter, compared to analysts’ expectations of $0.69 million. MediWound had a negative net margin of 752.78% and a negative return on equity of 326.32%. The business’s quarterly revenue was up 93.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.34) EPS. On average, equities research analysts predict that MediWound Ltd. will post ($0.76) EPS for the current year.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its stake in shares of MediWound by 19.7% in the 1st quarter. Wells Fargo & Company MN now owns 53,241 shares of the biopharmaceutical company’s stock valued at $351,000 after buying an additional 8,745 shares during the period. Wellington Management Group LLP boosted its stake in shares of MediWound by 11.0% in the 1st quarter. Wellington Management Group LLP now owns 2,157,839 shares of the biopharmaceutical company’s stock valued at $14,241,000 after buying an additional 213,745 shares during the period. Migdal Insurance & Financial Holdings Ltd. boosted its stake in shares of MediWound by 20.3% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 2,028,112 shares of the biopharmaceutical company’s stock valued at $13,791,000 after buying an additional 342,165 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of MediWound by 1.7% in the 1st quarter. Renaissance Technologies LLC now owns 75,600 shares of the biopharmaceutical company’s stock valued at $499,000 after buying an additional 1,300 shares during the period. Institutional investors and hedge funds own 23.47% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/21/mediwound-ltd-mdwd-trading-down-17-4.html.

MediWound Company Profile

MediWound Ltd. is a biopharmaceutical company. The Company focuses on developing, manufacturing and commercializing therapeutics products in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders and other indications. The Company’s product, NexoBrid, is indicated for the removal of dead or damaged tissue, known as eschar, in adults with deep partial- and full-thickness thermal burns, also referred to as severe burns.

Receive News & Stock Ratings for MediWound Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound Ltd. and related stocks with our FREE daily email newsletter.